Data as of Apr 17
| +1.33 / +12.94%|
The 2 analysts offering 12-month price forecasts for Galectin Therapeutics Inc have a median target of 29.50, with a high estimate of 32.00 and a low estimate of 27.00. The median estimate represents a +154.09% increase from the last price of 11.61.
The current consensus among 2 polled investment analysts is to Buy stock in Galectin Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.